|
J Biol Chem, Vol. 275, Issue 17, 13082-13088, April 28, 2000
An NF-Y Binding Site Is Important for Basal, but Not
Gonadotropin-releasing Hormone-stimulated, Expression of the
Luteinizing Hormone Subunit Gene*
Ruth A.
Keri,
Daniel J.
Bachmann,
Alireza
Behrooz,
Brian D.
Herr,
Rebecca K.
Ameduri,
Christine C.
Quirk, and
John H.
Nilson
From the Department of Pharmacology, Case Western Reserve
University, Cleveland, Ohio 44106
 |
ABSTRACT |
Regulated synthesis of luteinizing hormone (LH)
requires coordinated transcriptional control of the and LH
subunits in pituitary gonadotropes. Several cis-acting
elements and trans-acting factors have been defined for
control of the LH promoter through heterologous cell culture models.
In this report, we describe the identification of bipartite NF-Y
(CBF/CP1) binding sites within the proximal bovine LH promoter. When
multimerized, one of these sites activates the heterologous, minimal
HSV thymidine kinase promoter in the gonadotrope-derived cell line
T3-1. The functional role of the promoter-distal site in regulating
the full-length bovine LH promoter was assessed in vivo
using transgenic mice harboring a mutant promoter linked to the
chloramphenicol acetyltransferase reporter gene. While this element is
important for conferring high level activity of the LH promoter in
pituitary, it does not appear to be essential for mediating
gonadotropin-releasing hormone (GnRH) regulation. This is the first
characterization of a cis-acting element within this
GnRH-dependent promoter that is restricted to regulating
basal expression and not GnRH-induced activity.
 |
INTRODUCTION |
Stimulation of gametogenesis and synthesis of sex steroids by
luteinizing hormone (LH)1 is
essential for reproduction in all mammalian species. Thus, understanding the regulated synthesis and secretion of this hormone from the gonadotropes in the pituitary is paramount to understanding the reproductive process.
LH is a member of the glycoprotein hormone family whose members are
composed of a shared subunit that combines with unique, hormone-defining subunits. Synthesis and secretion of LH requires coordinated, gonadotrope-specific expression of the genes encoding both
the and LH subunits (1). Gonadotrope-specific expression of the
subunit gene requires a number of cis-acting elements located within the promoter-proximal 400 bp of the 5'-flanking region
of the gene (2-7). Discernment of the essential cis-acting elements involved in expression of the LH subunit has lagged behind
that made for the subunit due to the lack of readily accessible,
appropriate model systems.
Five models have been used to uncover regulatory elements within the
LH promoter. These include cell lines corresponding to kidney
fibroblasts (CV-1) (8, 9), modified somatotropes (GGH3-1')
(10, 11), primordial gonadotropes ( T3-1) (12-14), and
differentiated gonadotropes (L T2) (15, 16) as well as transgenic
mice (17-21). Using these approaches, four transcription factors have
been identified that regulate expression of the LH subunit gene
through direct binding to its promoter (see Fig. 1A). These
include the orphan nuclear receptor, SF-1 (8, 15, 21), an early growth
response protein, Egr-1 (22, 23), a bicoid-related
homeodomain protein, Pitx1 (9), and the ubiquitous transcription
factor, Sp1 (11). There are two Egr-1 and SF-1 binding sites that exist
in a pairwise conformation interrupted by a Pitx1 binding site within
the promoter-proximal 150 bp (24). This configuration is conserved
across many, if not all, mammalian LH promoters. Numerous recent
studies have shown that SF-1 and Egr-1 functionally cooperate to
activate transcription (16, 24, 25) of the LH subunit gene. In
addition, Pitx1 further potentiates the activation mediated by these
two proteins; however, this does not appear to require direct binding
of Pitx1 to DNA (25). Rather, Pitx1 can interact directly with SF-1 and
Egr-1 to induce expression (25). Sp1 regulates the rat LH promoter by binding two elements that reside further upstream in the promoter at
( 451/ 428) and ( 411/ 386) (11). This region is less conserved across species than the promoter-proximal sequences, and its importance in other species remains to be determined.
The relative importance of Egr-1, SF-1, and Pitx1 in regulating LH
gene expression has been confirmed with targeted disruption of each
gene in mice. Mice deficient in Egr-1 exhibit a specific loss of LH
gene expression, while the and follicle-stimulating hormone genes remain functional (22, 23). This suggests that Egr-1 is a
selective transcriptional regulator of the LH gene and may mediate
differential regulation of LH and follicle-stimulating hormone within
the same cell. In contrast, mice deficient in SF-1 have a reduced
gonadotrope population accompanied by attenuated expression of all
three gonadotropin genes (26). Whether this is due solely to a defect
within the gonadotrope (21) or to an additional impact in the
hypothalamus (27) remains to be determined. Targeted disruption of
the Pitx1 gene leads to gross defects in limb development (28, 29)
as well as multiple pituitary effects (28). Although gonadotrope number
and expression of the gonadotropin genes is significantly reduced in
these animals, there is not an ablation of either (28). Thus, while
Pitx1 is important for LH gene expression and gonadotrope
development, it does not appear to be essential.
While earlier work focused on evaluating basal expression of the LH
subunit gene, this rapidly evolved into analyses of the effects of
gonadotropin-releasing hormone (GnRH). This reflects the exquisite
dependence of transcriptional activity of the LH gene on pulsatile
release of GnRH from the hypothalamus, exemplified by the
hpg/hpg mouse (30) that harbors a spontaneous deletion of
this gene (31). Mice harboring this mutation express the LH subunit
gene at only 5-10% of normal levels (32), suggesting that "basal"
activity of this gene requires activation of GnRH-induced signaling
cascades. Indeed, all of the factors described to date as being
important for LH gene expression also contribute to GnRH induction
(11, 13, 14, 16, 21, 24, 25). In the current manuscript, we report the
identification of an additional pairwise cis-acting element
that binds NF-Y (CBF/CP1). In contrast to the previously described
cis-acting elements and their cognate factors characterized
for this gene, these sites are the first to be described that solely
affect basal expression of this gene.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Radiolabeled nucleotides and chloramphenicol were
obtained from NEN Life Science Products. Acetyl coenzyme A and the GnRH antagonist, antide, were from Sigma. DNA-modifying enzymes were from
either Roche Molecular Biochemicals or Life Technologies, Inc.
Sequenase version 2.0 was from Amersham Pharmacia Biotech. Poly(dI-dC)
was purchased from Roche Molecular Biochemicals. Sp1 antibody was
obtained from Santa Cruz Biotechnology, Inc., and NF-Y (A
subunit-specific) antibody was from Rockland Immunochemicals.
Plasmid Constructs--
The HSVtk-luc vector was constructed by
inserting an XhoI/SalI fragment containing the
HSVtk minimal promoter ( 105/+5) from BLCAT2 (33) into the
XhoI site of pGL2-Basic (Promega). Kinased, double-stranded
oligodeoxynucleotides corresponding to L 1 or L 2 (see below) were
ligated into the SacI site 5' to the thymidine kinase
promoter. The number and orientation of elements was then determined by
dideoxynucleotide sequencing.
A transversion mutation of the L 1 site within the context of the
full-length ( 776/+10)bLH promoter was accomplished using an
oligodeoxynucleotide replacement approach in the previously described
( 776/+10)bLH CAT vector (18). Oligodeoxynucleotides corresponding
to the region to be mutated were
5'-CCGGGAACCGACAACGATTCCCCGGTTCAGAGGGGCGGTGCTGCA-3' and 5'-GCACCGCCCCTCTGAACCGGGGAATCGTTGTCGGTTCCCGG-3',
with the mutant sequence indicated with boldface letters. The
annealed oligodeoxynucleotide has a 5' blunt end and a 3'
PstI overhang. The annealed, double-stranded
oligodeoxynucleotide was inserted into the PstI sites at
397 and 355, relative to the start site of transcription, that
flank the L 1 consensus site. This required conversion of the 5'
PstI site into a blunt end prior to ligation with the mutant
oligonucleotide. The composition of the resultant clone was confirmed
by sequencing the region containing the mutation and restriction
digests confirming the remainder of the expression cassette. Isolation
of the transgene was accomplished by restriction digestion with
SalI and BamHI.
Cell Culture/Transient Transfections--
Transient transfection
assays of T3-1 and MCF-7 cells were performed essentially as
described (7) using 1.2 µg of test vector and 0.42 µg of RSV -gal
per 35-mm2 well containing 110,000-170,000 cells. Cells
were harvested 48 h post-transfection in 150 µl of reporter
lysis buffer (Promega). Luciferase and -galactosidase assays were
performed as previously reported (7).
Electrophoretic Mobility Shift Assays (EMSAs)--
Nuclear
extracts from T3-1, MCF-7, and BeWo cells were prepared as described
previously (7). EMSAs were performed essentially as described (21)
except with 5-10 µg of nuclear protein. The following
oligodeoxynucleotides were used (lowercase type indicates SacI sites added for cloning purposes): L 1(+),
5'-cTGCAGCCAATCACCATCGGAAAATTGagct-3'; L 1( ),
5'-CAATTTTCCGATGGTGATTGGCTGCAgagct-3'; L 1 µ6 10(+),
5'-cTGCAGTCAACACCATCGGAAAATTGagct-3'; L 1 µ6 10( ),
5'-CAATTTTCCGATGGTGTTGACTGCAgagct-3'; L 1 10 µ18(+), 5'-cTGCAGCCAACACCATCTGAAAATTGagct-3'; L 1 10 µ18( ),
5'-CAATTTTCAGATGGTGTTGGCTGCAgagct-3'; L 1 µ18/25(+),
5'-cTGCAGCCAATCACCATCTGAAAATGGagct-3'; L 1 µ18/25( ), 5'-CCATTTTCAGATGGTGATTGGCTGCAgagct-3'; L 1 µ6(+),
5'-cTGCAGTCAATCACCATCGGAAAATTGagct-3'; L 1 µ6( ),
5'-CAATTTTCGATGGTGATTGACTGCAgagct-3'; L 2(+),
5'-cTGTGAAGTCACCTTCTCCTGGGTGagct-3'; L 2( ),
5'-CACCCAAGGAGAAGGTGACTTCACAgagct-3'; B 1(+),
5'-CTGCAGTCAACACCATCTGAAAATGGA-3'; B 1( ),
5'-CCATTTTCAGATGGTGTTGACTGCAGA-3' and an Sp1 consensus oligodeoxynucleotide obtained from Promega Corp. Double-stranded oligodeoxynucleotides were end-labeled with
[ -32P]ATP using polynucleotide kinase. For the
antibody supershift experiments, binding reactions were performed with
5-10 µg of T3-1 nuclear extract and 1 µg of poly(dI-dC) in 10 mM Tris-HCl (pH 7.4), 50 mM NaCl, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, and 4% glycerol in a total volume of 15 µl. After a 30-min incubation on ice, 5 × 104 cpm
of labeled probe was added with an additional 30-min incubation on ice.
For reactions containing antibody, 1 µl of anti-Sp1 or anti-NF-Y was
added during the initial 30-min incubation.
Transgenic Mice--
All mice were housed in microisolator-plus
units under pathogen-free conditions. Food and water were given
ad libitum, and animals were subjected to a 12-h light/dark
cycle. Mice harboring the ( 776/+10)bLH CAT construct have been
previously described (18). For this work, we regenerated this
transgenic strain to utilize mice that were as few generations from the
founder animals as possible for direct comparison with mice harboring
the µL 1 construct.
To generate mice with the ( 776/+10)µL 1bLH CAT construct, the
2.4-kilobase pair expression cassette was liberated with
SalI plus BamHI. Transgenic mouse production,
identification, and characterization of tissue-specific expression were
done as reported (18). Chloramphenicol acetyltransferase (CAT) assays
were performed as described (18) with 10-25 µg of cellular lysate
for 1 or 4 h. Each assay contained control tissues from mice
containing the wild type promoter. The amount of lysate used in each
CAT assay was identical for each sample within that assay.
The ovariectomy/antide treatment paradigm was performed as follows.
Female mice harboring either the wild type or mutant promoter were
ovariectomized under avertin anesthesia. Following surgery, randomized
mice were separated into two groups: those receiving vehicle (20%
propylene glycol in saline) injections and those receiving antide
injections. 60 µg of antide was given as a subcutaneous injection
every 48 h for 10 days. On day 10, mice were killed by
asphyxiation in a CO2 chamber, and cardiac blood,
pituitaries, and livers were collected. All animals used were adults
and age-matched (within 1 month) within individual experiments. All
animal studies were approved by the Case Western Reserve University
Institutional Animal Care and Use Committee.
 |
RESULTS |
Alignment of the Bovine and LH Promoters Reveals Three
Conserved Regions--
Production of LH requires coordinated
expression of both the and LH genes. These genes must be
expressed concurrently in a temporal and spatial pattern to form an
intact heterodimer. In addition, regulation of their expression by GnRH
and gonadal steroids may involve similar mechanisms for the two genes.
Thus, we speculated that specific cis-acting elements may be
shared between the two gonadotropin subunit genes as a means to confer similar signals for regulated expression. To begin to identify targets
for functional analysis of the LH promoter in transgenic animals, we
examined the bovine gonadotropin promoters for regions of apparent
conservation. Three regions with greater than 80% homology were
identified (Fig. 1B). One of
these, the GSE, was previously shown to be important for activity of
both the (5) and LH (8, 21) genes. The other two elements
located at positions 399/ 372 (element L 1) and 228/ 204
(element L 2) relative to the start site of transcription of the
bovine LH gene, were subject to further analyses to determine their
role, if any, in activating the LH promoter. A diagrammatic sketch of the positions of these elements as well as others identified for the
bovine or rat genes is shown in Fig. 1A.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
Alignment of the bovine and LH promoters reveals three conserved
regions. A, a schematic diagram of the bovine LH
promoter with the position of L 1 and L 2 is shown. Binding sites
for SF-1 (GSE), Egr-1, and Pitx1 are indicated. The positions of Sp1
binding sites that are present within the rat LH promoter are also
shown. L 4 harbors a sequence that binds the same protein as L 1.
The Sp1 site that is 5' to the L 1 site is outlined in
gray to reflect the lack of an Sp1 consensus at this site in
the bovine promoter. B, the bovine and LH subunits
were scanned for any regions of conservation between the two promoters.
The sequences of three conserved elements are indicated. The GSE has
previously been described (5, 8, 21). Element 1 and element 2 are
designated L 1 and L 2 when referring to the elements within the
LH promoter.
|
|
L 1, but Not L 2, Stimulates Transcriptional Activity of a
Minimal Thymidine Kinase Promoter--
In the absence of GnRH, the
bovine LH promoter has low activity in transiently transfected cells
(18) that precludes functional analyses of the L 1 and L 2 elements
in the context of the full-length promoter. Therefore, functional
activity was initially assessed by determining whether multimerized
L 1 or L 2 elements could stimulate expression of the HSVtk minimal
promoter when linked to luciferase. The resulting constructs were
transiently transfected into T3-1 cells. As shown in Fig.
2, the L 1 element was capable of
activating the HSVtk promoter 2-3-fold with inverted repeats of this
sequence resulting in the greatest induction. In contrast, L 2 was
incapable of activating the heterologous promoter. Similar results were
obtained in the breast cancer cell line, MCF-7 (data not shown). The
ability of L 1 to function independently of cell lineage suggested
that it might bind a factor that is not gonadotrope-specific.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 2.
L 1, but not
L 2, stimulates transcriptional activity of a
minimal thymidine kinase promoter. Oligodeoxynucleotides
corresponding to L 1 or L 2 were multimerized and ligated upstream
of the HSVtk minimal promoter linked to luciferase. A shaded
(L 1) or black (L 2) box indicates the
presence and orientation (arrowheads) of each element.
T3-1 cells were transiently transfected with each construct. Values
are expressed relative to HSVtk-luc activity and represent the
mean ± S.E. of three independent experiments each with three
replicates.
|
|
L 1, but Not L 2, Binds a Nuclear Factor That Is Common to a
Variety of Cell Lines--
To determine if L 1 and L 2 elements
bind nuclear proteins, EMSAs were performed with T3-1 nuclear
extracts. This assay revealed that L 1 could bind a single complex
with high specificity and affinity (Fig.
3A). While only a 50-100-fold
molar excess of homologous competitor was necessary to eliminate
binding of the factor to the probe, a 100-fold molar excess of
heterologous competitor (LH GSE (21)) had no impact on protein
binding. A monophasic Scatchard analysis revealed a high affinity
interaction between the nuclear protein and the L 1 site
(KD = 1.2 × 10 10 M,
data not shown) that was well within the known range for eukaryotic transcription factors that bind to DNA (34). In contrast to L 1,
incubation of the L 2 probe with T3-1 nuclear extract failed to
reveal any high affinity complexes (Fig. 3A). This supports data obtained from the transient transfection studies and suggests that
L 2 is nonfunctional in these cells. Given the transcriptional activity and protein binding function of L 1, we chose to focus on
further characterization of this element. Whether L 2 has a transcriptional function in mature gonadotropes remains to be determined. Studies aimed at addressing this issue will probably involve complex experimental paradigms such as transgenic mice and
preparation of nuclear extracts from mature gonadotrope cells.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 3.
L 1 binds a nuclear
factor that is common to a variety of cell lines. A,
EMSA were performed with either the L 1 or L 2 probes and T3-1
nuclear extracts. A single complex was observed with the L 1 probe.
To assess binding specificity, competition analyses were performed by
adding 10-, 50-, or 100-fold molar excess of unlabeled, homologous
L 1 or L 2 (as indicated) or heterologous GSE (21). Increasing
concentrations of added oligodeoxynucleotides are indicated by
triangles. B, EMSA were accomplished with nuclear
extracts obtained from cell lines derived from gonadotrope ( T3-1),
choriocarcinoma (BeWo), or mammary epithelium (MCF-7). The L 1 band
is indicated by an arrow. Competition analyses were
performed with unlabeled homologous L 1 or an L 1 mutant harboring
a C/T transition at position 6 (see Fig. 4A for the L 1
and mutant sequence).
|
|
To address whether the L 1 protein-binding complex was unique to
gonadotrope origin cell lines, we performed additional EMSA studies
using nuclear extracts from MCF-7 and BeWo cells. Both extracts
exhibited a complex with the same mobility and competition profile as
that observed with T3-1 nuclear extracts (Fig. 3B). An
additional complex displaying a faster migration pattern was also
observed in both heterologous extracts. This interaction was considered
nonspecific due to the increase in intensity that corresponded with
increasing concentrations of unlabeled competitors. From these results,
we conclude that the protein(s) that bind to LB1 are not cell-specific
and are likely to be ubiquitous given their distribution in
gonadotrope-, mammary-, and choriocarcinoma-derived cell lines.
The L 1 Element Contains a CCAAT Motif That Is Essential for
Protein Binding--
To begin to discern whether the L 1 element was
functionally conserved in the bovine subunit promoter, we performed
EMSA with its L 1 homolog, designated B 1. Interestingly, although homology analysis was utilized to originally identify L 1, the B 1
element did not bind any proteins with high affinity in EMSA with
T3-1 nuclear extracts (data not shown). While function of the B 1
element within the context of the full-length subunit promoter was
not addressed, lack of protein binding in gonadotrope-derived cells
suggests that this region was not important for transcriptional function of the bovine subunit gene promoter.
Only four nucleotide differences exist between the L 1 and B 1
elements. Thus, the lack of high affinity binding of a nuclear protein
to B 1 could be used to rapidly discern the specific nucleotides required for protein binding to L 1. Mutations in the L 1 element were made to mimic those nucleotide differences observed in B 1. Fig.
4A outlines the mutant
oligodeoxynucleotides utilized in EMSA. Two nucleotide changes were
within a CCAAT motif, while two additional differences were external to
this motif. The importance of these particular nucleotides in protein
binding was addressed using pairwise mutations and competition analysis
in EMSA utilizing the wild type L 1 probe. As shown in Fig.
4B, mutation of nucleotides at positions 6 and 10 within
L 1 eliminated the ability of this oligonucleotide to compete for
binding to the wild type L 1 probe. Similar to the 6/10 mutation,
mutation of nucleotides 10 and 18 also resulted in loss of L 1
protein binding. In contrast, pairwise mutation of the two nucleotides
outside the CCAAT motif at positions 18 and 24 resulted in no change in
affinity. These results implicate the position 10 nucleotide (the T of
CCAAT) in protein binding and minimized the likelihood that binding
involved specific sequences eight nucleotides downstream of the CCAAT
motif. To directly assess the importance of the C at position 6 of
L 1, an additional point mutant was used in EMSA. This mutant was
incapable of competing with protein binding to the wild type L 1
probe (Fig. 3B). Thus, both the initial C and the T of the
CCAAT motif are essential for protein binding to L 1.

View larger version (83K):
[in this window]
[in a new window]
|
Fig. 4.
The L 1 element
contains a CCAAT motif that is essential for protein binding.
A, alignment of the element 1 sequences from the bovine (B 1) and LH (L 1) promoters reveals only four nucleotide
differences between the two that must dictate binding activity. These
differences are indicated by boldface letters,
and the position of each is denoted. B, EMSA with T3-1
nuclear extracts and L 1 probe. Unlabeled L 1 competitor
(i.e. wild type) was added at 10- and 50-fold molar excess.
Unlabeled mutant L 1 oligonucleotide competitors were added at 50-, 100-, and 300-fold molar excess. The mutations within the L 1
oligodeoxynucleotides are indicated by the position of the mutation. At
each of these positions, the sequence was converted from the LH
promoter sequence to that present within the promoter.
|
|
NF-Y Is the L 1-binding Protein--
The requirement for
sequences corresponding to a CCAAT motif suggested that the L 1
element might bind to a known CCAAT box-binding factor. To begin to
determine the nature of the CCAAT-binding protein that interacts with
L 1, we performed a variety of competition EMSA studies with
consensus oligodeoxynucleotides and antisera to known CCAAT box-binding
factors. Antiserum directed against NF-Y was capable of
"supershifting" the L 1 protein band (Fig. 5A). NF-Y is a ubiquitous
transcription factor that binds to CCAAT motifs. Thus, the protein that
interacts with L 1 is either NF-Y or a highly related protein. Within
the rat LH promoter, an Sp1 site that resides just 5' to the NF-Y
binding site was shown to be important for mediating GnRH regulation.
No Sp1 consensus binding sequence exists in the bovine promoter at this
site; however, to determine if Sp1 could also bind to the L 1
element, we performed additional EMSA. Antiserum to the transcription
factor Sp1 did not affect binding of nuclear factors to the L 1
element but did retard the mobility of a complex formed with an
oligodeoxynucleotide corresponding to a consensus Sp1 element (Fig.
5A). Thus, we conclude that NF-Y, but not Sp1, binds to this
site in the bovine LH promoter.

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 5.
NF-Y is the L 1- and
L 4-binding protein. A, EMSA
were performed with T3-1 nuclear extracts and either L 1-, L 4-,
or Sp1-labeled probes. Supershift assays were performed with antisera
directed against NF-Y or Sp1 to assess the nature of the protein
complexes associated with these oligodeoxynucleotide probes.
Supershifted complexes containing either NF-Y or Sp1 are indicated with
arrows. B, the L 1 and L 2 core CCAAT
elements are aligned with the NF-Y consensus sequence (36). The L 1
site harbors an exact consensus sequence for NF-Y. Lowercase
letters indicates mismatches from the consensus. The full
sequences of the probes used in the EMSA are delineated under
"Experimental Procedures."
|
|
The L 1 Element Exists as an Inverted Repeat in the Bovine LH
Promoter--
Subsequent analysis of the bovine LH promoter for
additional CCAAT motifs surprisingly indicated that no motif was
present in the region surrounding 80 bp relative to the start site of transcription. In contrast, as shown in Fig. 5B, an
additional imperfect motif (CCTAT) was observed in the opposing
orientation of the LH promoter at positions 332 to 328. This
sequence, within the context of a larger oligodeoxynucleotide
(designated L 4), was analyzed for its ability to bind a nuclear
protein in EMSA (Fig. 5A). Interestingly, L 4 bound the
same protein as L 1 as shown by complete cross-competition and
antibody supershift experiments. However, L 4 bound this protein with
significantly lower affinity. While only a 100-fold molar excess of
unlabeled L 1 is required to compete for binding to the L 1 probe,
over 500-fold molar excess of unlabeled L 4 is required for a similar level of competition (data not shown). It is intriguing that the inverted orientation of the L 4 and L 1 elements within the LH promoter is identical to the most active multimerized L 1 elements in
transient transfection (Fig. 2). Inverted repeats of NF-Y sites have
been identified in multiple genes, suggesting that these sequences may
cooperate to lead to full expression of the LH promoter (35).
The L 1 Element Regulates Pituitary-specific Expression of the
Bovine LH Promoter--
To determine the functional importance of
the L 1 element in the context of a full-length promoter in an
appropriate physiological context, transgenic mice were made. These
mice harbored the 776-bp bovine LH promoter containing a
transversion mutation throughout the entire 26-bp region of the L 1
element linked to CAT. Pituitary CAT activity in these mice was
compared with that observed in mice harboring the wild type promoter
linked to CAT. Previous studies have shown that the full-length, wild
type promoter is highly active only in gonadotropes of transgenic mice
(18). In addition, the promoter responds appropriately to GnRH and
gonadal steroids (18). Pituitary CAT activity from six independent
lines of mice harboring the mutant LH promoter was compared with
activity observed in three independent lines of mice harboring the wild type promoter. Mutation of the L 1 element reduced activity of the
LH promoter to approximately 14% of the wild type promoter's activity (Fig. 6). While this reduction
was substantial, it is important to note that the L 1 mutant promoter
had detectable activity in a number of mice. In particular, mutant
lines 1, 3, and 4 displayed higher activity than the other lines of
mice harboring the mutation. This suggests that while L 1 is
important for high level expression of the LH promoter, some
integration sites permit low level expression from this attenuated
promoter. Thus, the remaining cis-acting elements must
compensate to some degree for the loss of the distal NF-Y binding
site.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 6.
The L 1 element
regulates pituitary-specific expression of the bovine
LH promoter. Transgenic mice harboring
either the wild type (wt, gray bars)
or an L 1 mutant (µ, black bars) LH
promoter linked to CAT were made. Pituitary CAT activity was measured
in three lines of mice with the wild type promoter and six lines of
mice harboring the mutant promoter. Values are the mean ± S.E.
The following numbers of animals were used: 29 (wt1), 44 (wt2), 11 (wt3), 12 (µ1), 5 (µ2), 8 (µ3), 6 (µ4), 1 (µ5), and 1 (µ6).
The µ5 and µ6 animals were founder transgenics. In all animals in
which liver activity was examined, it was below detection and similar
to the levels of activity observed in µ3, µ5, and µ6 animals.
Expression of the wild type transgene versus the mutant
transgene was significantly different (p 0.0001, two-tailed Student's t test assuming unequal
variances).
|
|
L 1 Is Unnecessary for GnRH Regulation of the LH
Promoter--
Numerous cis-acting elements have been
described for the LH promoter, and most, if not all, mediate GnRH
stimulation (11, 14, 16, 21, 24, 25). To determine the role of the
L 1 element in conveying GnRH regulation, female transgenic mice
harboring either the wild type promoter or the L 1 mutant promoter
were subjected to an ovariectomy/antide treatment paradigm. Ovariectomy removes negative feedback from ovarian steroids and causes an increase
in GnRH synthesis and secretion from the hypothalamus that further
results in increased LH gene expression (1). Treatment with the
GnRH-specific antagonist, antide, can block this increase (18). Thus,
the degree of repression of transgene activity following antide
administration is an indicator of the degree of promoter responsiveness
to GnRH. To assess the impact of the L 1 mutation, mice were
ovariectomized and treated with either vehicle or antide for 10 days.
As previously shown (18, 21), antide treatment lead to a 38-63%
reduction in wild type promoter activity in two independent lines of
mice (Fig. 7). Similarly, antide
treatment of ovariectomized mice harboring the L 1 mutation resulted
in 50% reduction in promoter function. This indicates that while the
basal function of the LH promoter is significantly attenuated by
mutation of the L 1 element, this element is not necessary for
mediating GnRH-regulated expression. Whether NF-Y can mediate GnRH
regulation through the intact L 4 site or additional, uncharacterized, binding sites is unknown and warrants further study.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 7.
L 1 is unnecessary
for GnRH regulation of the LH promoter.
Transgenic mice harboring either the wild type (wt) or
mutant (µL 1) ( 776/+10) LH promoter were subjected
to a GnRH regulation assay. The mutant line used in this study
corresponds to µ1 in Fig. 6. Mice were ovariectomized and treated
with either vehicle (OVX, gray bars)
or 60 µg antide (OVX + antide, black
bars) every 48 h. for 10 days. Pituitaries were
collected, and CAT enzymatic activity was measured. Values are
expressed relative to the OVX control for each line of mice and
represent the mean ± S.E., n = 5 animals per
group. In each case, antide treatment resulted in CAT activity that was
significantly different from OVX animals (p 0.05, one-tailed Student's t test assuming unequal
variances).
|
|
 |
DISCUSSION |
Expression of luteinizing hormone in the gonadotrope of the
pituitary requires the coordinated expression of the and LH subunits. Both subunit genes respond to GnRH and sex steroids to
promote synthesis and secretion of appropriate levels of the intact
heterodimer (1). Several elements have been defined for transcriptional
control of both the and LH subunit genes. However, a complete
picture of LH gene regulation has not been resolved. This has
largely been due to the lack of appropriate cell culture models to
study expression of this gene.
Using transgenic mice, we and others have shown that the LH
promoter-proximal region confers high level expression that is confined
to gonadotropes and responds appropriately to GnRH and gonadal steroids
(17-20). In this report, we describe an inverted repeat element that
binds to NF-Y and is important for full activity of the LH promoter
in transgenic mice. In contrast to the other elements that have been
described thus far for this promoter, the distal NF-Y binding site is
not required for mediating GnRH responsiveness. Thus, two different
classes of cis-active elements exist for the LH promoter.
These include basal and GnRH-responsive sites, both of which contribute
to transcriptional tone. Since expression of the LH gene is very low
in the absence of GnRH (32), the so-called basal elements may play a
role in amplifying a signal that must be initiated by GnRH acting
through the promoter-proximal SF-1, Pitx1, and Egr-1 binding sites, as
well as potential Sp1 sites.
NF-Y is a ubiquitous CCAAT box-binding factor that is composed of three
subunits (36). It regulates both TATA-containing and TATA-less
promoters (35). Functional NF-Y sites within promoters are usually
closely associated with the start site of transcription, occurring
within the promoter-proximal 100 bp (36). However, there are several
genes that contain NF-Y binding sites that are over 1 kilobase pairs 5'
to the promoter (35). Both the L 1 and L 4 sites are located more
distally than the typical NF-Y site. In addition, this factor displays
an almost strict requirement for the pentanucleotide CCAAT motif that
can occur on either the coding or noncoding strand (35, 36). While
L 1 harbors an exact consensus for NF-Y, the L 4 site has a CCTAT
motif on the opposite strand from L 1. Although the L 4 site also
binds NF-Y, it does so with lower affinity than L 1 (data not shown).
The L 4 motif has been observed in the cdc25 gene (37) as
well as the MHC Class II DPA gene (38). Interestingly, these
sequences, like L 4, all occurred in the reverse orientation on the
coding strand. Unlike the LH subunit gene, however, both of these
genes are TATA-less.
There are numerous examples of NF-Y cooperativity with other
transcription factors (39-41). It is particularly interesting to note
that NF-Y can synergize with the transcription factor Sp1 (39, 41). An
Sp1 site has been characterized within the rat LH promoter that is
immediately adjacent to a conserved NF-Y sequence (11). Whether these
two proteins synergize to activate the rat promoter remains to be
determined. With regard to LH promoters from other species, the Sp1
sequence is not conserved at this site, although the adjacent NF-Y
sequence is. Within the bovine LH promoter, we have shown that an
oligodeoxynucleotide that encompasses the NF-Y site fails to bind Sp1.
Thus, the transcriptional regulation that occurs through this
cis-acting element cannot be attributed to Sp1. It will be
important to determine if Sp1 consensus sequences located within other
regions of this promoter can bind to Sp1 and potentially synergize with
the NF-Y binding sites to activate transcription.
Sp1 and the other factors that define transcriptional activity of the
LH promoter have largely been characterized using heterologous cell
culture systems. These include the use of kidney fibroblasts (CV-1) (8,
9, 22), somatotropes (GH3 and GGH3-1') (10, 11, 24), and immature
gonadotropes ( T3-1) (13-15). None of these cell lines express the
endogenous LH subunit gene, and they are probably devoid of
essential factors for activating its transcription. While these models
have allowed ascertainment of the ability of specific transcription
factors to induce the LH promoter, most depended upon overexpression
of those factors. Thus, the relative importance of these factors in
defining the transcriptional tone of the LH promoter within the
mature gonadotrope is unknown. The recently derived L T2 cell line,
which does express the endogenous LH subunit gene (42), will
probably present an ideal avenue to confirm studies previously
performed in these alternative models. Prior to development of this
cell line, however, the only mature gonadotrope model effectively used
for analyses of the LH promoter was the pituitary of transgenic
mice. Even with this cell line, the transgenic mouse presents the most
physiologically relevant system to assess important factors in
regulating expression of the LH gene. In this regard, we have
characterized a new site that is important for basal expression of this
gene but not GnRH induction. The function of this element contrasts
with the previously defined GSE that was shown to be essential for
pituitary activity as well as GnRH activation of this promoter in
transgenic mice (21). While previous in vivo and in
vitro studies have focused specifically on the promoter-proximal
150 bp, the studies presented herein indicate that additional sequences
involved in regulation of promoter activity reside upstream of this
region. Thus, any attempts to study the proximal promoter in isolation
will probably result in a limited picture of the transcription control
of this gene.
 |
ACKNOWLEDGEMENTS |
We acknowledge the Pharmacological Sciences
Consortium Core Transgenic Facility at Case Western Reserve University
for production of transgenic mice. We also thank David Peck for
excellent technical assistance and Paul MacDonald for helpful
discussions during the preparation of this manuscript.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DK28559 (to J. H. N.) and DK09843 (to C. C. Q.) and an
Endocrine Society fellowship (to B. D. H.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pharmacology,
Case Western Reserve University School of Medicine, 2109 Adelbert Rd.,
Cleveland, OH 44106. Tel.: 216-368-4497; Fax: 216-368-3395; E-mail:
jhn@po.cwru.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
LH, luteinizing
hormone;
SF-1, steroidogenic factor-1: GnRH, gonadotropin-releasing
hormone;
CAT, chloramphenicol acetyltransferase;
HSVtk, herpes simplex
virus thymidine kinase;
EMSA, electrophoretic mobility shift assay;
GSE, gonadotrope-specific element;
bp, base pair(s).
 |
REFERENCES |
| 1.
|
Gharib, S. D.,
Wierman, M. E.,
Shupnik, M. A.,
and Chin, W. W.
(1990)
Endocr. Rev.
11,
177-199[Abstract/Free Full Text]
|
| 2.
|
Bokar, J. A.,
Keri, R. A.,
Farmerie, T. A.,
Fenstermaker, R. A.,
Andersen, B. A.,
Hamernik, D. L.,
Yun, J.,
Wagner, T.,
and Nilson, J. H.
(1989)
Mol. Cell. Biol.
9,
5113-5122[Abstract/Free Full Text]
|
| 3.
|
Kay, T. W.,
and Jameson, J. L.
(1992)
Mol. Endocrinol.
6,
1767-1773[Abstract/Free Full Text]
|
| 4.
|
Schoderbek, W. E.,
Roberson, M. S.,
and Maurer, R. A.
(1993)
J. Biol. Chem.
268,
3903-3910[Abstract/Free Full Text]
|
| 5.
|
Barnhart, K. M.,
and Mellon, P. L.
(1994)
Mol. Endocrinol.
8,
878-885[Abstract/Free Full Text]
|
| 6.
|
Jackson, S. M.,
Gutierrez-Hartman, A.,
and Hoeffler, J. P.
(1995)
Mol. Endocrinol.
9,
278-291[Abstract/Free Full Text]
|
| 7.
|
Heckert, L. L.,
Schultz, K.,
and Nilson, J. H.
(1995)
J. Biol. Chem.
270,
26497-26504[Abstract/Free Full Text]
|
| 8.
|
Halvorson, L. M.,
Kaiser, U.,
and Chin, W. W.
(1996)
J. Biol. Chem.
271,
6645-6650[Abstract/Free Full Text]
|
| 9.
|
Tremblay, J. J.,
Lanctot, C.,
and Drouin, J.
(1998)
Mol. Endocrinol.
12,
428-441[Abstract/Free Full Text]
|
| 10.
|
Kaiser, U. B.,
Sabbagh, E.,
Saunders, B. D.,
and Chin, W. W.
(1998)
Endocrinology
139,
2443-2451[Abstract/Free Full Text]
|
| 11.
|
Kaiser, U. B.,
Sabbagh, E.,
Chen, M. T.,
Chin, W. W.,
and Saunders, B. D.
(1998)
J. Biol. Chem.
273,
12943-12951[Abstract/Free Full Text]
|
| 12.
|
Weck, J.,
Fallest, P. C.,
Pitt, L. K.,
and Shupnik, M. A.
(1998)
Mol. Endocrinol.
12,
451-457[Abstract/Free Full Text]
|
| 13.
|
Halvorson, L. M.,
Kaiser, U.,
and Chin, W. W.
(1999)
Mol. Endocrinol.
13,
106-116[Abstract/Free Full Text]
|
| 14.
|
Wolfe, M. W.,
and Call, G. B.
(1999)
Mol. Endocrinol.
13,
752-763[Abstract/Free Full Text]
|
| 15.
|
Wolfe, M. W.
(1999)
Mol. Endocrinol.
13,
1497-1510[Abstract/Free Full Text]
|
| 16.
|
Dorn, C.,
Ou, Q.,
Svaren, J.,
Crawford, P. A.,
and Sadovsky, Y.
(1999)
J. Biol. Chem.
274,
13870-13876[Abstract/Free Full Text]
|
| 17.
|
Brown, P.,
McNeilly, J. R.,
Wallace, R. M.,
McNeilly, A. S.,
and Clark, A. J.
(1993)
Mol. Cell. Endocrinol.
93,
157-165[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Keri, R. A.,
Wolfe, M. W.,
Saunders, T. L.,
Anderson, I.,
Kendall, S. K.,
Wagner, T.,
Yun, J.,
Gorski, J.,
Nett, T. M.,
Camper, S. A.,
and Nilson, J. H.
(1994)
Mol. Endocrinol.
8,
1807-1816[Abstract/Free Full Text]
|
| 19.
|
Fallest, P. C.,
Trader, G. L.,
Darrow, J. M.,
and Shupnik, M. A.
(1995)
Biol. Reprod.
53,
103-109[Abstract]
|
| 20.
|
McNeilly, J. R.,
Brown, P.,
Mullins, J.,
Clark, A. J.,
and McNeilly, A. S.
(1996)
J. Endocrinol.
151,
481-489[Abstract/Free Full Text]
|
| 21.
|
Keri, R. A.,
and Nilson, J. H.
(1996)
J. Biol. Chem.
271,
10782-10785[Abstract/Free Full Text]
|
| 22.
|
Lee, S. L.,
Sadovsky, Y.,
Swirnoff, A. H.,
Polish, J. A.,
Goda, P.,
Gavrilina, G.,
and Milbrandt, J.
(1996)
Science
273,
1219-1221[Abstract]
|
| 23.
|
Topilko, P.,
Schneider-Maunoury, S.,
Levi, G.,
Trembleau, A.,
Gourdji, D.,
Driancourt, M. A.,
Rao, C. V.,
and Charnay, P.
(1998)
Mol. Endocrinol.
12,
107-122[Abstract/Free Full Text]
|
| 24.
|
Halvorson, L. M.,
Ito, M.,
Jameson, J. L.,
and Chin, W. W.
(1998)
J. Biol. Chem.
273,
14712-14720[Abstract/Free Full Text]
|
| 25.
|
Tremblay, J. J.,
and Drouin, J.
(1999)
Mol. Cell. Biol.
19,
2567-2576[Abstract/Free Full Text]
|
| 26.
|
Ingraham, H. A.,
Lala, D. S.,
Ikeda, Y.,
Luo, X.,
Shen, W. H.,
Nachtigal, M. W.,
Abbud, R.,
Nilson, J. H.,
and Parker, K. L.
(1994)
Genes Dev.
8,
2302-2312[Abstract/Free Full Text]
|
| 27.
|
Ikeda, Y.,
Luo, X.,
Abbud, R.,
Nilson, J. H.,
and Parker, K. L.
(1995)
Mol. Endocrinol.
9,
478-486[Abstract/Free Full Text]
|
| 28.
|
Szeto, D. P.,
Rodriguez-Esteban, C.,
Ryan, A. K.,
O'Connell, S. M.,
Liu, F.,
Kioussi, C.,
Gleiberman, A. S.,
Izpisúa-Belmonte, J. C.,
and Rosenfeld, M. G.
(1999)
Genes Dev.
13,
484-494[Abstract/Free Full Text]
|
| 29.
|
Lanctot, C.,
Moreau, A.,
Chamberland, M.,
Tremblay, J. J.,
and Drouin, J.
(1999)
Development
126,
1805-1810[Abstract]
|
| 30.
|
Cattanach, B. M.,
Iddon, C. A.,
Charlton, H. M.,
Chiappa, S. A.,
and Fink, G.
(1977)
Nature
269,
338-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Mason, A. J.,
Hayflick, J. S.,
Zoeller, T.,
Young, W. S. I.,
Phillips, H. S.,
Nikolics, K.,
and Seeburg, P. H.
(1986)
Science
234,
1366-1371[Abstract/Free Full Text]
|
| 32.
|
Saade, G.,
London, D. R.,
and Clayton, R. N.
(1989)
Endocrinol.
124,
1744-1753[Abstract/Free Full Text]
|
| 33.
|
Quinn, P. G.
(1993)
J. Biol. Chem.
268,
16999-17009[Abstract/Free Full Text]
|
| 34.
|
Luisi, B.
(1995)
DNA-Protein: Structural Interactions
, pp. 1-48, IRL Press, Oxford
|
| 35.
|
Mantovani, R.
(1998)
Nucleic Acids Res.
26,
1135-1143[Abstract/Free Full Text]
|
| 36.
|
Maity, S. N.,
and de Crombrugghe, B.
(1998)
Trends Biochem. Sci.
23,
174-178[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Zwicker, J.,
Gross, C.,
Lucibello, F. C.,
Truss, M.,
Ehlert, F.,
Engeland, K.,
and Muller, R.
(1995)
Nucleic Acids Res.
23,
3822-3830[Abstract/Free Full Text]
|
| 38.
|
Turco, E.,
Manfras, B. J.,
Ge, L.,
Rudert, W. A.,
and Trucco, M.
(1990)
Immunogenetics
32,
117-128[Medline]
[Order article via Infotrieve]
|
| 39.
|
Wright, K. L.,
Moore, T. L.,
Vilen, B. J.,
Brown, A. M.,
and Ting, J. P.
(1995)
J. Biol. Chem.
270,
20978-20986[Abstract/Free Full Text]
|
| 40.
|
Alonso, C. R.,
Pesce, C. G.,
and Kornblihtt, A. R.
(1996)
J. Biol. Chem.
271,
22271-22279[Abstract/Free Full Text]
|
| 41.
|
Murakami, Y.,
Ikeda, U.,
Shimada, K.,
and Kawakimi, K.
(1997)
Biochim. Biophys. Acta
1352,
311-324[Medline]
[Order article via Infotrieve]
|
| 42.
|
Turgeon, J. L.,
Kimura, Y.,
Waring, D. W.,
and Mellon, P. L.
(1996)
Mol. Endocrinol.
10,
439-450[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
X. Zhu, A. S. Gleiberman, and M. G. Rosenfeld
Molecular Physiology of Pituitary Development: Signaling and Transcriptional Networks
Physiol Rev,
July 1, 2007;
87(3):
933 - 963.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. B. Salisbury, A. K. Binder, J. C. Grammer, and J. H. Nilson
Maximal Activity of the Luteinizing Hormone{beta}-Subunit Gene Requires {beta}-Catenin
Mol. Endocrinol.,
April 1, 2007;
21(4):
963 - 971.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zheng, J. Yang, Q. Jiang, Z. He, and L. M Halvorson
Liver receptor homologue-1 regulates gonadotrope function
J. Mol. Endocrinol.,
February 1, 2007;
38(2):
207 - 219.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Sato, K. Kitahara, T. Susa, T. Kato, and Y. Kato
Pituitary transcription factor Prop-1 stimulates porcine pituitary glycoprotein hormone {alpha} subunit gene expression.
J. Mol. Endocrinol.,
October 1, 2006;
37(2):
341 - 352.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Jiang, K.-H. Jeong, C. D Horton, and L. M Halvorson
Pituitary homeobox 1 (Pitx1) stimulates rat LH{beta} gene expression via two functional DNA-regulatory regions
J. Mol. Endocrinol.,
August 1, 2005;
35(1):
145 - 158.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. D. Cherrington, T. A. Farmerie, C. A. Lents, J. D. Cantlon, M. S. Roberson, and C. M. Clay
Activin Responsiveness of the Murine Gonadotropin-Releasing Hormone Receptor Gene Is Mediated by a Composite Enhancer Containing Spatially Distinct Regulatory Elements
Mol. Endocrinol.,
April 1, 2005;
19(4):
898 - 912.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-Y. Kam, K.-H. Jeong, E. R. Norwitz, E. M. Jorgensen, and U. B. Kaiser
Oct-1 and Nuclear Factor Y Bind to the SURG-1 Element to Direct Basal and Gonadotropin-Releasing Hormone (GnRH)-Stimulated Mouse GnRH Receptor Gene Transcription
Mol. Endocrinol.,
January 1, 2005;
19(1):
148 - 162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. E. West, G. E. Parker, J. J. Savage, P. Kiratipranon, K. S. Toomey, L. R. Beach, S. C. Colvin, K. W. Sloop, and S. J. Rhodes
Regulation of the Follicle-Stimulating Hormone {beta} Gene by the LHX3 LIM-Homeodomain Transcription Factor
Endocrinology,
November 1, 2004;
145(11):
4866 - 4879.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Jorgensen, C. C. Quirk, and J. H. Nilson
Multiple and Overlapping Combinatorial Codes Orchestrate Hormonal Responsiveness and Dictate Cell-Specific Expression of the Genes Encoding Luteinizing Hormone
Endocr. Rev.,
August 1, 2004;
25(4):
521 - 542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. R. Jacobs, D. Coss, S. M. McGillivray, and P. L. Mellon
Nuclear Factor Y and Steroidogenic Factor 1 Physically and Functionally Interact to Contribute to Cell-Specific Expression of the Mouse Follicle-Stimulating Hormone-{beta} Gene
Mol. Endocrinol.,
August 1, 2003;
17(8):
1470 - 1483.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. S. Ellsworth, B. R. White, A. T. Burns, B. D. Cherrington, A. M. Otis, and C. M. Clay
c-Jun N-Terminal Kinase Activation of Activator Protein-1 Underlies Homologous Regulation of the Gonadotropin-Releasing Hormone Receptor Gene in {alpha}T3-1 Cells
Endocrinology,
March 1, 2003;
144(3):
839 - 849.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Quirk, D. D. Seachrist, and J. H. Nilson
Embryonic Expression of the Luteinizing Hormone beta Gene Appears to Be Coupled to the Transient Appearance of p8, a High Mobility Group-related Transcription Factor
J. Biol. Chem.,
January 10, 2003;
278(3):
1680 - 1685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Nackley, W. Shea-Eaton, D. Lopez, and M. P. McLean
Repression of the Steroidogenic Acute Regulatory Gene by the Multifunctional Transcription Factor Yin Yang 1
Endocrinology,
March 1, 2002;
143(3):
1085 - 1096.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Jorgensen and J. H. Nilson
AR Suppresses Transcription of the LH{beta} Subunit by Interacting with Steroidogenic Factor-1
Mol. Endocrinol.,
September 1, 2001;
15(9):
1505 - 1516.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Quirk, K. L. Lozada, R. A. Keri, and J. H. Nilson
A Single Pitx1 Binding Site Is Essential for Activity of the LH{beta} Promoter in Transgenic Mice
Mol. Endocrinol.,
May 1, 2001;
15(5):
734 - 746.
[Abstract]
[Full Text]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|